Search research articles
Contact Us
Filters
Showing results (91-100 of 95) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 95 results.
European Journal of Cancer (Oxford, England : 1990)
|
March 31, 2015
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
Guillem Argilés, Mark P Saunders, Fernando Rivera, et al.
Lancet (London, England)
|
November 27, 2012
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, et al.
The Lancet. Oncology
|
July 18, 2015
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
Josep Tabernero, Heinz-Josef Lenz, Salvatore Siena, et al.
Journal of Pediatric Surgery
|
May 21, 2018
A descriptive model for a multidisciplinary unit for colorectal and pelvic malformations
Alejandra Vilanova-Sanchez, Devin R Halleran, Carlos A Reck-Burneo, et al.
Science Translational Medicine
|
February 25, 2021
Load-induced regulation of tendon homeostasis by SPARC, a genetic predisposition factor for tendon and ligament injuries
Tao Wang, Andrea Wagner, Renate Gehwolf, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 95) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 95 results.
European Journal of Cancer (Oxford, England : 1990)
|
March 31, 2015
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
Guillem Argilés, Mark P Saunders, Fernando Rivera, et al.
Lancet (London, England)
|
November 27, 2012
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, et al.
The Lancet. Oncology
|
July 18, 2015
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
Josep Tabernero, Heinz-Josef Lenz, Salvatore Siena, et al.
Journal of Pediatric Surgery
|
May 21, 2018
A descriptive model for a multidisciplinary unit for colorectal and pelvic malformations
Alejandra Vilanova-Sanchez, Devin R Halleran, Carlos A Reck-Burneo, et al.
Science Translational Medicine
|
February 25, 2021
Load-induced regulation of tendon homeostasis by SPARC, a genetic predisposition factor for tendon and ligament injuries
Tao Wang, Andrea Wagner, Renate Gehwolf, et al.
Page
of 10